首页 > 最新文献

Nature cancer最新文献

英文 中文
γδ T cells as critical anti-tumor immune effectors γδ T 细胞是关键的抗肿瘤免疫效应因子。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-26 DOI: 10.1038/s43018-024-00798-x
Marcel Arias-Badia, Ryan Chang, Lawrence Fong
While the effector cells that mediate anti-tumor immunity have historically been attributed to αβ T cells and natural killer cells, γδ T cells are now being recognized as a complementary mechanism mediating tumor rejection. γδ T cells possess a host of functions ranging from antigen presentation to regulatory function and, importantly, have critical roles in eliciting anti-tumor responses where other immune effectors may be rendered ineffective. Recent discoveries have elucidated how these differing functions are mediated by γδ T cells with specific T cell receptors and spatial distribution. Their relative resistance to mechanisms of dysfunction like T cell exhaustion has spurred the development of therapeutic approaches exploiting γδ T cells, and an improved understanding of these cells should enable more effective immunotherapies. Fong and colleagues provide a Review on γδ T cells as mediators of anti-tumor immunity, discuss their role in the tumor microenvironment and reflect on therapeutic approaches to exploit γδ T cells.
介导抗肿瘤免疫的效应细胞历来被认为是 αβ T 细胞和自然杀伤细胞,而 γδ T 细胞现在被认为是介导肿瘤排斥反应的补充机制。γδT细胞具有从抗原递呈到调节功能的一系列功能,重要的是,在其他免疫效应因子可能失效的情况下,γδT细胞在激发抗肿瘤反应方面发挥着关键作用。最新发现阐明了具有特定 T 细胞受体和空间分布的 γδ T 细胞是如何介导这些不同功能的。γδT细胞对T细胞衰竭等功能障碍机制具有相对抵抗力,这推动了利用γδT细胞的治疗方法的发展。
{"title":"γδ T cells as critical anti-tumor immune effectors","authors":"Marcel Arias-Badia, Ryan Chang, Lawrence Fong","doi":"10.1038/s43018-024-00798-x","DOIUrl":"10.1038/s43018-024-00798-x","url":null,"abstract":"While the effector cells that mediate anti-tumor immunity have historically been attributed to αβ T cells and natural killer cells, γδ T cells are now being recognized as a complementary mechanism mediating tumor rejection. γδ T cells possess a host of functions ranging from antigen presentation to regulatory function and, importantly, have critical roles in eliciting anti-tumor responses where other immune effectors may be rendered ineffective. Recent discoveries have elucidated how these differing functions are mediated by γδ T cells with specific T cell receptors and spatial distribution. Their relative resistance to mechanisms of dysfunction like T cell exhaustion has spurred the development of therapeutic approaches exploiting γδ T cells, and an improved understanding of these cells should enable more effective immunotherapies. Fong and colleagues provide a Review on γδ T cells as mediators of anti-tumor immunity, discuss their role in the tumor microenvironment and reflect on therapeutic approaches to exploit γδ T cells.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141766741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibiting PI3Kγ in acute myeloid leukemia 在急性髓性白血病中抑制 PI3Kγ。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-24 DOI: 10.1038/s43018-024-00791-4
Aaron J. Stonestrom, Ross L. Levine
The mainly hematologic expression profile of phosphatidylinositol-3-kinase-γ (PI3Kγ) makes it an attractive therapeutic target. Recent work from three independent groups shows that inhibiting PI3Kγ impairs the metabolism and growth of acute myeloid leukemia cells — a finding that justifies further mechanistic and clinical exploration.
磷脂酰肌醇-3-激酶-γ(PI3Kγ)的主要血液学表达特征使其成为一个有吸引力的治疗靶点。三个独立研究小组的最新研究表明,抑制 PI3Kγ 会影响急性髓性白血病细胞的新陈代谢和生长--这一发现为进一步的机理研究和临床探索提供了依据。
{"title":"Inhibiting PI3Kγ in acute myeloid leukemia","authors":"Aaron J. Stonestrom, Ross L. Levine","doi":"10.1038/s43018-024-00791-4","DOIUrl":"10.1038/s43018-024-00791-4","url":null,"abstract":"The mainly hematologic expression profile of phosphatidylinositol-3-kinase-γ (PI3Kγ) makes it an attractive therapeutic target. Recent work from three independent groups shows that inhibiting PI3Kγ impairs the metabolism and growth of acute myeloid leukemia cells — a finding that justifies further mechanistic and clinical exploration.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-assisted detection of lymph node metastases safely reduces costs and time 人工智能辅助检测淋巴结转移可安全地降低成本和缩短时间。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-24 DOI: 10.1038/s43018-024-00795-0
Our non-randomized single-center clinical trial demonstrates the safety, cost-saving and time-saving potential of artificial intelligence (AI) assistance in the detection of breast cancer metastases in sentinel lymph nodes. AI assistance shows important benefits for pathologists and the laboratory workflow, which are needed as cancer incidence and diagnostics continue to rise.
我们的非随机单中心临床试验证明了人工智能(AI)辅助检测前哨淋巴结乳腺癌转移的安全性、节约成本和时间的潜力。人工智能辅助技术为病理学家和实验室工作流程带来了重要的益处,随着癌症发病率和诊断率的不断上升,我们需要人工智能辅助技术。
{"title":"AI-assisted detection of lymph node metastases safely reduces costs and time","authors":"","doi":"10.1038/s43018-024-00795-0","DOIUrl":"10.1038/s43018-024-00795-0","url":null,"abstract":"Our non-randomized single-center clinical trial demonstrates the safety, cost-saving and time-saving potential of artificial intelligence (AI) assistance in the detection of breast cancer metastases in sentinel lymph nodes. AI assistance shows important benefits for pathologists and the laboratory workflow, which are needed as cancer incidence and diagnostics continue to rise.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using machine learning to translate tumor dependencies 利用机器学习翻译肿瘤依赖关系。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-23 DOI: 10.1038/s43018-024-00790-5
Cancer dependency maps have accelerated the discovery of essential genes and potential drug targets. Here we used machine learning to build translational dependency maps of patients’ tumors and normal tissue biopsies, which identified oncogenes and synthetic lethalities that are predictive of drug responses and patients’ outcomes.
癌症依赖性图谱加速了重要基因和潜在药物靶点的发现。在这里,我们利用机器学习建立了患者肿瘤和正常组织活检的转化依赖图谱,从而确定了可预测药物反应和患者预后的癌基因和合成致死基因。
{"title":"Using machine learning to translate tumor dependencies","authors":"","doi":"10.1038/s43018-024-00790-5","DOIUrl":"10.1038/s43018-024-00790-5","url":null,"abstract":"Cancer dependency maps have accelerated the discovery of essential genes and potential drug targets. Here we used machine learning to build translational dependency maps of patients’ tumors and normal tissue biopsies, which identified oncogenes and synthetic lethalities that are predictive of drug responses and patients’ outcomes.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting the risk of prostate cancer recurrence through the lens of evolution 从进化的角度预测前列腺癌复发的风险。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-23 DOI: 10.1038/s43018-024-00792-3
Current prostate cancer risk predictors are not able to fully capture a patient’s risk of recurrence at the time of diagnosis. Evolutionary metrics of tumor diversity, based on low-cost sequencing and digital pathology, might provide a new dimension of information to close the gap between prediction and outcome.
目前的前列腺癌风险预测指标无法完全反映患者在诊断时的复发风险。基于低成本测序和数字病理学的肿瘤多样性进化指标可能会提供新的信息维度,缩小预测与结果之间的差距。
{"title":"Predicting the risk of prostate cancer recurrence through the lens of evolution","authors":"","doi":"10.1038/s43018-024-00792-3","DOIUrl":"10.1038/s43018-024-00792-3","url":null,"abstract":"Current prostate cancer risk predictors are not able to fully capture a patient’s risk of recurrence at the time of diagnosis. Evolutionary metrics of tumor diversity, based on low-cost sequencing and digital pathology, might provide a new dimension of information to close the gap between prediction and outcome.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinants of resistance and response to melanoma therapy 黑色素瘤治疗耐药性和反应的决定因素。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-17 DOI: 10.1038/s43018-024-00794-1
Bailey M. Robertson, Mitchell E. Fane, Ashani T. Weeraratna, Vito W. Rebecca
Metastatic melanoma is among the most enigmatic advanced cancers to clinically manage despite immense progress in the way of available therapeutic options and historic decreases in the melanoma mortality rate. Most patients with metastatic melanoma treated with modern targeted therapies (for example, BRAFV600E/K inhibitors) and/or immune checkpoint blockade (for example, anti-programmed death 1 therapy) will progress, owing to profound tumor cell plasticity fueled by genetic and nongenetic mechanisms and dichotomous host microenvironmental influences. Here we discuss the determinants of tumor heterogeneity, mechanisms of therapy resistance and effective therapy regimens that hold curative promise. Rebecca and colleagues discuss the complex biology of metastatic melanoma, as well as determinants of resistance to therapy and existing and promising therapy strategies.
尽管现有的治疗方案取得了巨大进步,而且黑色素瘤的死亡率也出现了历史性的下降,但转移性黑色素瘤仍是临床治疗中最令人费解的晚期癌症之一。大多数接受现代靶向疗法(如 BRAFV600E/K 抑制剂)和/或免疫检查点阻断疗法(如抗程序性死亡 1疗法)治疗的转移性黑色素瘤患者的病情都会进展,这是由于肿瘤细胞在遗传和非遗传机制以及二元宿主微环境影响下具有极强的可塑性。在此,我们将讨论肿瘤异质性的决定因素、耐药机制以及有望治愈的有效治疗方案。
{"title":"Determinants of resistance and response to melanoma therapy","authors":"Bailey M. Robertson, Mitchell E. Fane, Ashani T. Weeraratna, Vito W. Rebecca","doi":"10.1038/s43018-024-00794-1","DOIUrl":"10.1038/s43018-024-00794-1","url":null,"abstract":"Metastatic melanoma is among the most enigmatic advanced cancers to clinically manage despite immense progress in the way of available therapeutic options and historic decreases in the melanoma mortality rate. Most patients with metastatic melanoma treated with modern targeted therapies (for example, BRAFV600E/K inhibitors) and/or immune checkpoint blockade (for example, anti-programmed death 1 therapy) will progress, owing to profound tumor cell plasticity fueled by genetic and nongenetic mechanisms and dichotomous host microenvironmental influences. Here we discuss the determinants of tumor heterogeneity, mechanisms of therapy resistance and effective therapy regimens that hold curative promise. Rebecca and colleagues discuss the complex biology of metastatic melanoma, as well as determinants of resistance to therapy and existing and promising therapy strategies.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Building a translational cancer dependency map for The Cancer Genome Atlas 为癌症基因组图谱建立转化癌症依赖关系图。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-15 DOI: 10.1038/s43018-024-00789-y
Xu Shi, Christos Gekas, Daniel Verduzco, Sakina Petiwala, Cynthia Jeffries, Charles Lu, Erin Murphy, Tifani Anton, Andy H. Vo, Zhiguang Xiao, Padmini Narayanan, Bee-Chun Sun, Aloma L. D’Souza, J. Matthew Barnes, Somdutta Roy, Cyril Ramathal, Michael J. Flister, Zoltan Dezso
Cancer dependency maps have accelerated the discovery of tumor vulnerabilities that can be exploited as drug targets when translatable to patients. The Cancer Genome Atlas (TCGA) is a compendium of ‘maps’ detailing the genetic, epigenetic and molecular changes that occur during the pathogenesis of cancer, yet it lacks a dependency map to translate gene essentiality in patient tumors. Here, we used machine learning to build translational dependency maps for patient tumors, which identified tumor vulnerabilities that predict drug responses and disease outcomes. A similar approach was used to map gene tolerability in healthy tissues to prioritize tumor vulnerabilities with the best therapeutic windows. A subset of patient-translatable synthetic lethalities were experimentally tested, including PAPSS1/PAPSS12 and CNOT7/CNOT78, which were validated in vitro and in vivo. Notably, PAPSS1 synthetic lethality was driven by collateral deletion of PAPSS2 with PTEN and was correlated with patient survival. Finally, the translational dependency map is provided as a web-based application for exploring tumor vulnerabilities. Shi et al. present a hybrid dependency map based on machine-learning analysis of gene essentiality data from the DEPMAP database, translated to data from TCGA. This application can be used to visualize other gene essentiality data.
癌症依赖性图谱加速了对肿瘤弱点的发现,这些弱点一旦转化为病人,就可以作为药物靶点加以利用。癌症基因组图谱(TCGA)是一个 "图谱 "汇编,详细描述了癌症发病过程中发生的遗传、表观遗传和分子变化,但它缺乏一个依赖性图谱来转化患者肿瘤中的基因本质。在这里,我们利用机器学习建立了患者肿瘤的转化依赖性图谱,确定了可预测药物反应和疾病结果的肿瘤弱点。我们还采用类似的方法绘制了健康组织中的基因耐受性图谱,以优先考虑具有最佳治疗窗口的肿瘤弱点。对患者可翻译的合成致死基因进行了实验测试,包括 PAPSS1/PAPSS12 和 CNOT7/CNOT78,并在体外和体内进行了验证。值得注意的是,PAPSS1 合成致死性是由 PAPSS2 与 PTEN 的旁系缺失驱动的,并且与患者的存活率相关。最后,转化依赖性图谱作为一种基于网络的应用提供,用于探索肿瘤的脆弱性。
{"title":"Building a translational cancer dependency map for The Cancer Genome Atlas","authors":"Xu Shi, Christos Gekas, Daniel Verduzco, Sakina Petiwala, Cynthia Jeffries, Charles Lu, Erin Murphy, Tifani Anton, Andy H. Vo, Zhiguang Xiao, Padmini Narayanan, Bee-Chun Sun, Aloma L. D’Souza, J. Matthew Barnes, Somdutta Roy, Cyril Ramathal, Michael J. Flister, Zoltan Dezso","doi":"10.1038/s43018-024-00789-y","DOIUrl":"10.1038/s43018-024-00789-y","url":null,"abstract":"Cancer dependency maps have accelerated the discovery of tumor vulnerabilities that can be exploited as drug targets when translatable to patients. The Cancer Genome Atlas (TCGA) is a compendium of ‘maps’ detailing the genetic, epigenetic and molecular changes that occur during the pathogenesis of cancer, yet it lacks a dependency map to translate gene essentiality in patient tumors. Here, we used machine learning to build translational dependency maps for patient tumors, which identified tumor vulnerabilities that predict drug responses and disease outcomes. A similar approach was used to map gene tolerability in healthy tissues to prioritize tumor vulnerabilities with the best therapeutic windows. A subset of patient-translatable synthetic lethalities were experimentally tested, including PAPSS1/PAPSS12 and CNOT7/CNOT78, which were validated in vitro and in vivo. Notably, PAPSS1 synthetic lethality was driven by collateral deletion of PAPSS2 with PTEN and was correlated with patient survival. Finally, the translational dependency map is provided as a web-based application for exploring tumor vulnerabilities. Shi et al. present a hybrid dependency map based on machine-learning analysis of gene essentiality data from the DEPMAP database, translated to data from TCGA. This application can be used to visualize other gene essentiality data.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43018-024-00789-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
p53 at the crossroads of tumor immunity p53 处于肿瘤免疫的十字路口。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-15 DOI: 10.1038/s43018-024-00796-z
Gizem Efe, Anil K. Rustgi, Carol Prives
The p53 tumor suppressor protein has a plethora of cell-intrinsic functions and consequences that impact diverse cell types and tissues. Recent studies are beginning to unravel how wild-type and mutant p53 work in distinct ways to modulate tumor immunity. This sets up a disequilibrium between tumor immunosurveillance and escape therefrom. The ability to exploit this emerging knowledge for translational approaches may shape immunotherapy and targeted therapeutics in the future, especially in combinatorial settings. Prives and colleagues comprehensively discuss the current knowledge on cancer-related mutations of p53 and the impact they have on anticancer immunity.
p53 肿瘤抑制蛋白具有大量的细胞内在功能和后果,影响着不同的细胞类型和组织。最近的研究开始揭示野生型和突变型 p53 如何以不同的方式调节肿瘤免疫。这就造成了肿瘤免疫监视和逃避免疫监视之间的不平衡。利用这一新兴知识进行转化的能力可能会影响未来的免疫疗法和靶向疗法,尤其是在组合疗法中。
{"title":"p53 at the crossroads of tumor immunity","authors":"Gizem Efe, Anil K. Rustgi, Carol Prives","doi":"10.1038/s43018-024-00796-z","DOIUrl":"10.1038/s43018-024-00796-z","url":null,"abstract":"The p53 tumor suppressor protein has a plethora of cell-intrinsic functions and consequences that impact diverse cell types and tissues. Recent studies are beginning to unravel how wild-type and mutant p53 work in distinct ways to modulate tumor immunity. This sets up a disequilibrium between tumor immunosurveillance and escape therefrom. The ability to exploit this emerging knowledge for translational approaches may shape immunotherapy and targeted therapeutics in the future, especially in combinatorial settings. Prives and colleagues comprehensively discuss the current knowledge on cancer-related mutations of p53 and the impact they have on anticancer immunity.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer 肿瘤演变指标可预测局部晚期前列腺癌 10 年后的复发。
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-12 DOI: 10.1038/s43018-024-00787-0
Javier Fernandez-Mateos, George D. Cresswell, Nicholas Trahearn, Katharine Webb, Chirine Sakr, Andrea Lampis, Christine Stuttle, Catherine M. Corbishley, Vasilis Stavrinides, Luis Zapata, Inmaculada Spiteri, Timon Heide, Lewis Gallagher, Chela James, Daniele Ramazzotti, Annie Gao, Zsofia Kote-Jarai, Ahmet Acar, Lesley Truelove, Paula Proszek, Julia Murray, Alison Reid, Anna Wilkins, Michael Hubank, Ros Eeles, David Dearnaley, Andrea Sottoriva
Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics requires quantitative measurements in controlled clinical trials. We mapped genomic intratumor heterogeneity in locally advanced prostate cancer using 642 samples from 114 individuals enrolled in clinical trials with a 12-year median follow-up. We concomitantly assessed morphological heterogeneity using deep learning in 1,923 histological sections from 250 individuals. Genetic and morphological (Gleason) diversity were independent predictors of recurrence (hazard ratio (HR) = 3.12 and 95% confidence interval (95% CI) = 1.34–7.3; HR = 2.24 and 95% CI = 1.28–3.92). Combined, they identified a group with half the median time to recurrence. Spatial segregation of clones was also an independent marker of recurrence (HR = 2.3 and 95% CI = 1.11–4.8). We identified copy number changes associated with Gleason grade and found that chromosome 6p loss correlated with reduced immune infiltration. Matched profiling of relapse, decades after diagnosis, confirmed that genomic instability is a driving force in prostate cancer progression. This study shows that combining genomics with artificial intelligence-aided histopathology leads to the identification of clinical biomarkers of evolution. Sottoriva and colleagues combine next-generation sequencing and AI-aided histopathology to assess tumor evolvability in patient samples with long-term follow-up and find that it can be a strong predictor of recurrence in high-risk prostate cancer.
癌症演变为预测性肿瘤学奠定了基础。测试进化指标需要在对照临床试验中进行定量测量。我们利用临床试验中114人的642份样本绘制了局部晚期前列腺癌的肿瘤内基因组异质性图谱,中位随访期为12年。同时,我们还利用深度学习对来自 250 名患者的 1923 个组织学切片进行了形态学异质性评估。遗传和形态学(Gleason)多样性是复发的独立预测因素(危险比 (HR) = 3.12,95% 置信区间 (95% CI) = 1.34-7.3;HR = 2.24,95% CI = 1.28-3.92)。综合来看,他们发现了一个复发时间中位数为一半的群体。克隆的空间隔离也是复发的独立标志(HR = 2.3,95% CI = 1.11-4.8)。我们确定了与格里森分级相关的拷贝数变化,并发现染色体 6p 缺失与免疫浸润减少相关。对诊断后数十年的复发进行匹配分析,证实基因组不稳定性是前列腺癌进展的驱动力。这项研究表明,将基因组学与人工智能辅助组织病理学相结合,可以鉴定出进化的临床生物标志物。
{"title":"Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer","authors":"Javier Fernandez-Mateos, George D. Cresswell, Nicholas Trahearn, Katharine Webb, Chirine Sakr, Andrea Lampis, Christine Stuttle, Catherine M. Corbishley, Vasilis Stavrinides, Luis Zapata, Inmaculada Spiteri, Timon Heide, Lewis Gallagher, Chela James, Daniele Ramazzotti, Annie Gao, Zsofia Kote-Jarai, Ahmet Acar, Lesley Truelove, Paula Proszek, Julia Murray, Alison Reid, Anna Wilkins, Michael Hubank, Ros Eeles, David Dearnaley, Andrea Sottoriva","doi":"10.1038/s43018-024-00787-0","DOIUrl":"10.1038/s43018-024-00787-0","url":null,"abstract":"Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics requires quantitative measurements in controlled clinical trials. We mapped genomic intratumor heterogeneity in locally advanced prostate cancer using 642 samples from 114 individuals enrolled in clinical trials with a 12-year median follow-up. We concomitantly assessed morphological heterogeneity using deep learning in 1,923 histological sections from 250 individuals. Genetic and morphological (Gleason) diversity were independent predictors of recurrence (hazard ratio (HR) = 3.12 and 95% confidence interval (95% CI) = 1.34–7.3; HR = 2.24 and 95% CI = 1.28–3.92). Combined, they identified a group with half the median time to recurrence. Spatial segregation of clones was also an independent marker of recurrence (HR = 2.3 and 95% CI = 1.11–4.8). We identified copy number changes associated with Gleason grade and found that chromosome 6p loss correlated with reduced immune infiltration. Matched profiling of relapse, decades after diagnosis, confirmed that genomic instability is a driving force in prostate cancer progression. This study shows that combining genomics with artificial intelligence-aided histopathology leads to the identification of clinical biomarkers of evolution. Sottoriva and colleagues combine next-generation sequencing and AI-aided histopathology to assess tumor evolvability in patient samples with long-term follow-up and find that it can be a strong predictor of recurrence in high-risk prostate cancer.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43018-024-00787-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141600622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance 表皮生长因子受体(EGFR)和 PI3K 的一流选择性抑制剂为靶向适应性抗药性提供了单分子方法
IF 23.5 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-11 DOI: 10.1038/s43018-024-00781-6
Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel A. Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S. Sebolt-Leopold
Despite tremendous progress in precision oncology, adaptive resistance mechanisms limit the long-term effectiveness of molecularly targeted agents. Here we evaluated the pharmacological profile of MTX-531 that was computationally designed to selectively target two key resistance drivers, epidermal growth factor receptor and phosphatidylinositol 3-OH kinase (PI3K). MTX-531 exhibits low-nanomolar potency against both targets with a high degree of specificity predicted by cocrystal structural analyses. MTX-531 monotherapy uniformly resulted in tumor regressions of squamous head and neck patient-derived xenograft (PDX) models. The combination of MTX-531 with mitogen-activated protein kinase kinase or KRAS-G12C inhibitors led to durable regressions of BRAF-mutant or KRAS-mutant colorectal cancer PDX models, resulting in striking increases in median survival. MTX-531 is exceptionally well tolerated in mice and uniquely does not lead to the hyperglycemia commonly seen with PI3K inhibitors. Here, we show that MTX-531 acts as a weak agonist of peroxisome proliferator-activated receptor-γ, an attribute that likely mitigates hyperglycemia induced by PI3K inhibition. This unique feature of MTX-531 confers a favorable therapeutic index not typically seen with PI3K inhibitors. Sebolt-Leopold and colleagues design and develop a small-molecule inhibitor that can target both epidermal growth factor receptor and phosphatidylinositol 3-OH kinase, which can be leveraged to overcome resistance to targeted therapies in vivo.
尽管精准肿瘤学取得了巨大进展,但适应性耐药机制限制了分子靶向药物的长期有效性。在这里,我们评估了 MTX-531 的药理学特征,MTX-531 经过计算设计,可选择性地靶向两个关键的耐药性驱动因素--表皮生长因子受体和磷脂酰肌醇 3-OH 激酶(PI3K)。MTX-531 对这两个靶点都具有低纳摩尔效力,而且通过共晶体结构分析预测具有高度特异性。MTX-531单药治疗可使头颈部鳞癌患者异种移植(PDX)模型的肿瘤一致缩小。MTX-531与丝裂原活化蛋白激酶激酶或KRAS-G12C抑制剂联用,可使BRAF突变或KRAS突变结直肠癌PDX模型的肿瘤持久消退,从而显著提高中位生存期。MTX-531 对小鼠的耐受性特别好,而且不会导致 PI3K 抑制剂常见的高血糖。在这里,我们发现 MTX-531 是一种过氧化物酶体增殖激活受体-γ 的弱激动剂,这一特性可能会减轻 PI3K 抑制引起的高血糖。MTX-531的这一独特特性赋予了它PI3K抑制剂通常不具备的良好治疗指数。
{"title":"A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance","authors":"Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel A. Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S. Sebolt-Leopold","doi":"10.1038/s43018-024-00781-6","DOIUrl":"10.1038/s43018-024-00781-6","url":null,"abstract":"Despite tremendous progress in precision oncology, adaptive resistance mechanisms limit the long-term effectiveness of molecularly targeted agents. Here we evaluated the pharmacological profile of MTX-531 that was computationally designed to selectively target two key resistance drivers, epidermal growth factor receptor and phosphatidylinositol 3-OH kinase (PI3K). MTX-531 exhibits low-nanomolar potency against both targets with a high degree of specificity predicted by cocrystal structural analyses. MTX-531 monotherapy uniformly resulted in tumor regressions of squamous head and neck patient-derived xenograft (PDX) models. The combination of MTX-531 with mitogen-activated protein kinase kinase or KRAS-G12C inhibitors led to durable regressions of BRAF-mutant or KRAS-mutant colorectal cancer PDX models, resulting in striking increases in median survival. MTX-531 is exceptionally well tolerated in mice and uniquely does not lead to the hyperglycemia commonly seen with PI3K inhibitors. Here, we show that MTX-531 acts as a weak agonist of peroxisome proliferator-activated receptor-γ, an attribute that likely mitigates hyperglycemia induced by PI3K inhibition. This unique feature of MTX-531 confers a favorable therapeutic index not typically seen with PI3K inhibitors. Sebolt-Leopold and colleagues design and develop a small-molecule inhibitor that can target both epidermal growth factor receptor and phosphatidylinositol 3-OH kinase, which can be leveraged to overcome resistance to targeted therapies in vivo.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":null,"pages":null},"PeriodicalIF":23.5,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43018-024-00781-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141586965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nature cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1